PerkinElmer acquires BioLegend for $5.25B

By The Science Advisory Board staff writers

September 20, 2021 -- PerkinElmer announced it has completed its $5.25 billion acquisition of life science antibody and reagent company BioLegend, a deal first announced in July.

The acquisition expands PerkinElmer's life science portfolio into cytometry, proteogenomics, multiplex assays, recombinant proteins, magnetic cell separation, and bioprocessing.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.